AC Immune is a clinical stage biopharmaceutical company focused on developing medicine for neurodegenerative diseases. Co.'s clinical stage product candidates include: ACI-35.030, which targets pathological Tau and is intended as a disease-modifying treatment for Alzheimer's disease (AD) and other Tauopathies; Semorinemab, which is designed to slow the prion-like propagation of Tau pathology; ACI-24, in which it owns the global rights to ACI-24 and it develops ACI-24 in-house for AD and Down syndrome-related AD; and diagnostic candidates, in which it continues to develop its complementary diagnostic product candidates for Tau, a-syn (with Life Molecular Imaging SA) and TDP-43. The ACIU stock yearly return is shown above.
The yearly return on the ACIU stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ACIU annual return calculation with any dividends reinvested as applicable (on ex-dates).
|